Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

Scientific Posters & Presentations

Year

Presentation of RESTORE-ALS Phase 3 Trial Design at 2024 Annual NEALS Meeting

Oct 23, 2024

Supporting Materials

Presentation of RESTORE-ALS Phase 3 Trial Design at 2024 Annual NEALS Meeting 16.6 MB

Presentation of HEALEY ALS Platform Trial - Open Label Extension Results at 2024 ENCALS Meeting

Jun 18, 2024

Supporting Materials

Presentation of HEALEY ALS Platform Trial - Open Label Extension Results at 2024 ENCALS Meeting 7.2 MB

Presentation of VISIONARY-MS Long Term Extension Results at 2024 AAN Annual Meeting

Apr 16, 2024

Supporting Materials

AAN 2024 – VISIONARY-MS LTE Presentation 3.7 MB

AAN 2024 – VISIONARY-MS LTE Poster 4.3 MB

Presentation of VISIONARY-MS Long-Term Extension Results at ACTRIMS Forum 2024

Feb 29, 2024

Supporting Materials

VS-MS ACTRIMS 2024 6.1 MB

Survival Analyses of Clene Expanded Access Programs in ALS

Feb 22, 2024

Supporting Materials

Survival Analyses of Clene Expanded Access Programs in ALS 6 MB

Clinical Trials Update at 2024 International Alliance of ALS/MND Associations

Jan 25, 2024

Supporting Materials

Clinical Trials Update at 2024 International Alliance of ALS/MND Associations 2.5 MB

Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations, 2023 AAN Annual Meeting

Apr 25, 2023

Supporting Materials

AAN 2023 – CNM-Au8 Survival Benefit 5.8 MB

Presentation of VISIONARY-MS Trial Results by Michael Barnett, MBBS PhD FRACP FRCP, at the 2023 AAN Annual Meeting

Apr 25, 2023

Supporting Materials

AAN 2023 – VISIONARY-MS 9.1 MB

Clene Inc. Presentation of VISIONARY-MS Trial Results at ACTRIMS Forum 2023

Feb 23, 2023

Supporting Materials

VS-MS ACTRIMS 2023 8.6 MB

Presentation of VISIONARY-MS Trial Results by Michael Barnett, MBBS PhD FRACP FRCP, at PACTRIMS 2022

Nov 25, 2022

Supporting Materials

PACTRIMS Visionary - MS 4.4 MB

Clene Inc. Presentation of CNM-Au8 Topline Data From the HEALEY ALS Platform Trial

Oct 3, 2022

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open Label Extension Study at 2022 AANEM Annual Meeting

Sep 21, 2022

Supporting Materials

RESCUE-ALS OLE Poster - Survival 1.4 MB

Clene Inc. Presentation of RESCUE-ALS Trial Results at 2022 AANEM Annual Meeting

Sep 21, 2022

Supporting Materials

RESCUE-ALS Poster - Encore 1.9 MB

Clene Inc. – Phase 2 VISIONARY-MS Trial Results

Aug 15, 2022

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open Label Extension Study at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

RESCUE-ALS Poster - Survival 3.5 MB

RESCUE-ALS Poster - Quality of Life 3.9 MB

Clene Inc. Presentation of Preclinical Evidence for Neuroprotection by CNM-Au8 in Multiple in vitro Models of ALS at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

Preclinical ALS Poster 5.9 MB

Clene Inc. Presentation of RESCUE-ALS Trial Results at 2022 ENCALS Meeting

Jun 1, 2022

Supporting Materials

RESCUE-ALS Poster - Encore 5.7 MB

RESCUE-ALS Poster - Biomarker Findings 6.8 MB

Clene Inc. Presentation of Updated Interim Data from RESCUE-ALS Open-Label Extension Study at 2022 AAN Annual Meeting

Apr 5, 2022

Supporting Materials

Presentation 4.5 MB

Evidence for an ALS Survival Benefit with CNM-Au8 Treatment: Interim Results from the RESCUE-ALS Trial Long-Term Open Label Extension (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

RESCUE-ALS Open Label Extension Poster 26.7 MB

Evidence for Brain Energy Metabolic Support with CNM-Au8 Treatment: Results from the REPAIR Phase 2 Clinical Trials (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

REPAIR Poster 4.9 MB

RESCUE-ALS Trial Results: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in ALS (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

RESCUE-ALS Poster 5.7 MB

RESCUE-ALS Oral Presentation 5.6 MB

CNM-Au8 Gold Nanocatalysis Protects Neurons Against Degeneration and Death in Multiple in vitro Models of Amyotrophic Lateral Sclerosis (MDA Clinical & Scientific Conference 2022)

Mar 14, 2022

Supporting Materials

Preclinical ALS Poster 22.7 MB

VISIONARY-MS Blinded Interim Data Update at ACTRIMS Forum 2022

Feb 24, 2022

Supporting Materials

VISIONARY-MS Poster 2.9 MB

Improvement of Brain Energy Metabolism in Relapsing MS: Results from Phase 2 REPAIR-MS Clinical Trial With CNM-Au8 at ACTRIMS Forum 2022

Feb 24, 2022

Supporting Materials

REPAIR-MS Poster 3.2 MB

Clene Inc. Late-Breaking Presentation of RESCUE-ALS Clinical Trial Results at the 32nd International Symposium on ALS/MND

Dec 10, 2021

Supporting Materials

Presentation 4.9 MB

Clene Inc. Poster Presentation of RESCUE-ALS Clinical Trial Results at the 32nd International Symposium on ALS/MND

Dec 7, 2021

Supporting Materials

RESCUE-ALS Poster 8.5 MB

Clene Inc. Presentation of Updated Data from RESCUE-ALS Clinical Trial at the Annual ALS ONE Research Symposium

Nov 30, 2021

Supporting Materials

Presentation 13.2 MB

Clene Inc. Presentation of RESCUE-ALS Topline Clinical Trial Results

Nov 2, 2021

Supporting Materials

Presentation 23.4 MB

Results from Phase 2 REPAIR-MS Clinical Trial at ECTRIMS 2021

Oct 14, 2021

Supporting Materials

REPAIR-MS Presentation 23.4 MB

Updated Blinded Interim Phase 2 Data from VISIONARY-MS at ECTRIMS 2021

Oct 14, 2021

Supporting Materials

VISIONARY-MS Poster 2.7 MB

Clene Inc. Presentation at the MDS Virtual Congress 2021: Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8

Sep 17, 2021

Supporting Materials

Presentation 2.3 MB

Video Presentation

Blinded Interim Update on RESCUE-ALS: A Randomized, Placebo-Controlled, Phase 2 Study at ENCALS 2021

May 12, 2021

Audio Presentation

Supporting Materials

Presentation 7.7 MB

Updated Interim Phase 2 Data from REPAIR-MS at the 2021 ACTRIMS Forum

Feb 25, 2021

Supporting Materials

Presentation 7.9 MB

Updated Blinded Interim Phase 2 Data from VISIONARY-MS at the 2021 ACTRIMS Forum

Feb 25, 2021

Supporting Materials

Presentation 14 MB

Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MND

Nov 11, 2020

Supporting Materials

View the Abstract 6.4 MB

Presentation 792.8 KB

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2024 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | TERMS OF USE